The IP6K1 Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-mediated gene-disruption pool produced in the A-549 human lung adenocarcinoma epithelial cell line. This polyclonal knockout population, derived from Homo sapiens, enables investigation of inositol hexakisphosphate kinase 1 (IP6K1) function without the bias of single-cell cloning. IP6K1, which converts inositol hexakisphosphate (IP6) to diphosphoinositol pentakisphosphate (IP7), sits at the intersection of inositol phosphate metabolism, insulin signaling, mTOR signaling, and p53 signaling, making this model relevant for dissecting metabolic and oncogenic pathways.
A-549 cells are a well-characterized model of non-small-cell lung cancer, originally derived from a 58-year-old male patient with lung carcinoma. The adherent epithelial cells exhibit a hypotriploid karyotype and express markers of alveolar type II pneumocytes. This cell line is extensively used to study lung adenocarcinoma biology, including tumor suppressor mechanisms, oncogene-driven signaling, and drug response. The introduction of IP6K1 knockout into this context provides a platform to directly explore how inositol pyrophosphate metabolism influences lung cancer cell behavior.
IP6K1 catalyzes the production of 5-IP7, a high-energy pyrophosphate second messenger that regulates core cellular processes. The enzyme is activated by glucose, growth factors acting through the PI3K/AKT pathway, nutrient availability, and the tumor suppressor TP53. Once generated, IP7 modulates AKT, PDK1, mTORC1, and casein kinase 2 (CSNK2), thereby integrating metabolic and growth signals to control proliferation, survival, and apoptosis. Additionally, IP6K1 interacts with the COPI complex, importins, HSP90, and protein kinases, suggesting roles in trafficking, nuclear transport, and protein stability.
In the A-549 lung adenocarcinoma background, IP6K1 knockout disrupts a signaling node that connects nutrient sensing to cell fate decisions. Because IP6K1-derived IP7 modulates AKT/mTOR and p53 pathways, its loss is expected to alter metabolic adaptability, apoptosis thresholds, and migratory capacity??all critical traits in cancer progression. This model thus provides a defined system to test how inositol pyrophosphate signaling contributes to the aggressive phenotype of lung cancer cells and to evaluate the therapeutic potential of targeting IP6K1 in lung malignancies.
Researchers can use this polyclonal knockout population for cancer drug screening, metabolic disorder modeling, and signal transduction studies. Assays such as Western blotting for phosphorylated AKT, mTORC1, and p53, IP7 mass spectrometry, and functional tests for viability, migration, and apoptosis are directly applicable. Kinase activity assays allow investigation of PDK1 and CSNK2 downstream. Combining genetic knockout with pharmacological treatments enables mapping of IP6K1-dependent vulnerabilities. For further details, please contact Ascent Research.
